| scholarly article | Q13442814 |
| P50 | author | Giorgio Colombo | Q41044487 |
| Byoung Heon Kang | Q42805357 | ||
| Massimiliano Meli | Q58242166 | ||
| Len Neckers | Q89479068 | ||
| Dario C Altieri | Q98158352 | ||
| Bradley T Scroggins | Q114883608 | ||
| Kristin Beebe | Q29515234 | ||
| P2093 | author name string | Ho Young Song | |
| Janet Plescia | |||
| P2860 | cites work | Hsp90: a specialized but essential protein-folding tool | Q24291482 |
| Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones | Q24298081 | ||
| Disassembly of transcriptional regulatory complexes by molecular chaperones | Q24300055 | ||
| PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1 | Q24312106 | ||
| OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD | Q24312778 | ||
| Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia | Q24313505 | ||
| Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent | Q27736012 | ||
| The consensus coding sequences of human breast and colorectal cancers | Q27861035 | ||
| A control theoretic paradigm for cell signaling networks: a simple complexity for a sensitive robustness | Q36369079 | ||
| Barriers to efficient development of cancer therapeutics | Q36494874 | ||
| Targeting Hsp90 for the treatment of cancer. | Q36556620 | ||
| Development and application of Hsp90 inhibitors | Q37055392 | ||
| Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. | Q40063505 | ||
| The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line | Q40414429 | ||
| Rational design of shepherdin, a novel anticancer agent. | Q40422406 | ||
| A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors | Q40631570 | ||
| Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. | Q40707507 | ||
| Regulated and unregulated mitochondrial permeability transition pores: a new paradigm of pore structure and function? | Q52123671 | ||
| Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. | Q53523033 | ||
| Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. | Q53551868 | ||
| Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis | Q64377539 | ||
| Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins | Q73402066 | ||
| A Bax/Bak-independent mechanism of cytochrome c release | Q80099045 | ||
| The genomic landscapes of human breast and colorectal cancers | Q27861078 | ||
| The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore | Q28241418 | ||
| Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death | Q28242641 | ||
| Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death | Q28242653 | ||
| Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness | Q28261997 | ||
| Oncogenomics and the development of new cancer therapies | Q28263634 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis | Q28276567 | ||
| Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death | Q28297152 | ||
| Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death | Q28363890 | ||
| The Connectivity Map: a new tool for biomedical research | Q28530408 | ||
| Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia | Q28585666 | ||
| The pathophysiology of mitochondrial cell death | Q29547893 | ||
| Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation | Q30477813 | ||
| Highly efficient, nonpeptidic oligoguanidinium vectors that selectively internalize into mitochondria | Q30980809 | ||
| Structure and in vivo function of Hsp90. | Q33840745 | ||
| The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties | Q33888203 | ||
| Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome | Q33912989 | ||
| Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin | Q33972993 | ||
| Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells | Q34351215 | ||
| Heat shock protein 90 as a molecular target for cancer therapeutics | Q35099516 | ||
| Heat shock protein 90. | Q35587293 | ||
| Targeted cancer therapy | Q35953128 | ||
| The development of imatinib as a therapeutic agent for chronic myeloid leukemia | Q35993288 | ||
| Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection | Q36002989 | ||
| Can cell systems biology rescue drug discovery? | Q36138342 | ||
| Systems modeling: a pathway to drug discovery | Q36188268 | ||
| Compartmentalized signalling of Ras. | Q36206390 | ||
| Mitochondria: pharmacological manipulation of cell death | Q36274960 | ||
| Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function | Q36274969 | ||
| Promoting apoptosis as a strategy for cancer drug discovery | Q36292878 | ||
| Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology | Q36337927 | ||
| Mitochondrial medicine: pharmacological targeting of mitochondria in disease | Q36358060 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mitochondrion | Q39572 |
| P304 | page(s) | 454-464 | |
| P577 | publication date | 2009-02-23 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90 | |
| P478 | volume | 119 |
| Q49255117 | A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy |
| Q38752375 | A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems. |
| Q42149303 | A highly selective Hsp90 affinity chromatography resin with a cleavable linker |
| Q30833071 | A neuronal network of mitochondrial dynamics regulates metastasis |
| Q92635856 | Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors |
| Q33799516 | Anti-leukemia activity of a Hsp70 inhibitor and its hybrid molecules |
| Q36483749 | Broad targeting of resistance to apoptosis in cancer. |
| Q26796364 | Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion |
| Q26830028 | Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers |
| Q48798795 | Cellular Antisense Activity of PNA-Oligo(bicycloguanidinium) Conjugates Forming Self-Assembled Nanoaggregates |
| Q36655158 | Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease |
| Q37570374 | Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil |
| Q33812112 | Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim. |
| Q34192823 | Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain. |
| Q37396817 | Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones |
| Q36452803 | Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF-II cells |
| Q36738017 | Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s |
| Q34652973 | Crystallization and preliminary X-ray diffraction analysis of Trap1 complexed with Hsp90 inhibitors |
| Q24654354 | Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer |
| Q36385108 | Disabling mitochondrial reprogramming in cancer |
| Q38735183 | Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series |
| Q34755334 | Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells |
| Q27307854 | Geldanamycin derivative ameliorates high fat diet-induced renal failure in diabetes |
| Q33907712 | Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma |
| Q34316341 | Heat Shock Protein 60 Regulation of the Mitochondrial Permeability Transition Pore in Tumor Cells |
| Q93105038 | Heat Shock Protein 90 Ensures the Integrity of Rubella Virus p150 Protein and Supports Viral Replication |
| Q38008726 | Heat shock proteins in cancer: targeting the 'chaperones'. |
| Q37639711 | Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy |
| Q89053635 | Hsp90 inhibitors as senolytic drugs to extend healthy aging |
| Q37056146 | Hsp90 regulation of mitochondrial protein folding: from organelle integrity to cellular homeostasis |
| Q33882184 | Image-guided combination chemotherapy and photodynamic therapy using a mitochondria-targeted molecular probe with aggregation-induced emission characteristics |
| Q36627435 | Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. |
| Q28474354 | Induction of premature senescence by hsp90 inhibition in small cell lung cancer |
| Q47115416 | Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses |
| Q38796931 | Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function |
| Q34127625 | Insight into nanoparticle cellular uptake and intracellular targeting |
| Q43237773 | Integrating Enzymatic Self-Assembly and Mitochondria Targeting for Selectively Killing Cancer Cells without Acquired Drug Resistance. |
| Q37067115 | Landscape of the mitochondrial Hsp90 metabolome in tumours |
| Q30576959 | Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells |
| Q28468339 | Mitochondria targeting nano agents in cancer therapeutics (Review) |
| Q39400621 | Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. |
| Q90042455 | Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives |
| Q49374480 | Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension. |
| Q51834574 | Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer. |
| Q33804537 | Mitochondrial Hsp90s suppress calcium-mediated stress signals propagating from mitochondria to the ER in cancer cells |
| Q37873695 | Mitochondrial compartmentalized protein folding and tumor cell survival |
| Q38198085 | Mitochondrial dynamics: biology and therapy in lung cancer |
| Q39303215 | Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR. |
| Q41043950 | Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. |
| Q42426838 | Mitochondrial unfolded protein response controls matrix pre-RNA processing and translation |
| Q58769558 | Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment |
| Q64955421 | Mitohormesis Primes Tumor Invasion and Metastasis. |
| Q92702817 | Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer |
| Q38818474 | Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders. |
| Q36535726 | Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. |
| Q90406652 | Molecular Scaffolds as Double-Targeting Agents For the Diagnosis and Treatment of Neuroblastoma |
| Q37995191 | New insights into TRAP1 pathway |
| Q58092812 | Non-Peptidic Cell-Penetrating Motifs for Mitochondrion-Specific Cargo Delivery |
| Q57974086 | Non-peptidic cell-penetrating agents: synthesis of oligomeric chiral bicyclic guanidinium vectors |
| Q38101516 | Ocular toxicity assessment from systemically administered xenobiotics: considerations in drug development |
| Q38551234 | Organelle-specific Hsp90 inhibitors |
| Q27324467 | PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion |
| Q58597543 | PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia |
| Q37004579 | Past, present, and emerging roles of mitochondrial heat shock protein TRAP1 in the metabolism and regulation of cancer stem cells. |
| Q28477773 | Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer |
| Q34168636 | Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer |
| Q26823014 | Progress of molecular targeted therapies for prostate cancers |
| Q35227454 | Repercussion of Mitochondria Deformity Induced by Anti-Hsp90 Drug 17AAG in Human Tumor Cells |
| Q41134535 | Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. |
| Q38729252 | Role of FOXO transcription factors in crosstalk between mitochondria and the nucleus. |
| Q39869511 | Shock the heat shock network |
| Q34263419 | Signaling the mitochondrial unfolded protein response |
| Q35414966 | Sorafenib exerts anti-glioma activity in vitro and in vivo |
| Q37665298 | Subcellular targeting strategies for drug design and delivery |
| Q27329571 | Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion |
| Q33634679 | Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. |
| Q37924023 | TRAP-1, the mitochondrial Hsp90. |
| Q38664647 | TRAP1: a viable therapeutic target for future cancer treatments? |
| Q34628001 | Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. |
| Q34115304 | Targeting mitochondria for cancer therapy |
| Q40969918 | Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors |
| Q61817743 | Targeting strategies for improving the efficacy of nanomedicine in oncology |
| Q28288602 | Targeting the dynamic HSP90 complex in cancer |
| Q90511806 | The different axes of the mammalian mitochondrial unfolded protein response |
| Q39433767 | The effect of chronic alcohol consumption on mitochondrial calcium handling in hepatocytes. |
| Q36489298 | Tumor Necrosis Factor Receptor-associated Protein 1 (TRAP1) Mutation and TRAP1 Inhibitor Gamitrinib-triphenylphosphonium (G-TPP) Induce a Forkhead Box O (FOXO)-dependent Cell Protective Signal from Mitochondria |
| Q35911798 | Unfolded protein stress in the endoplasmic reticulum and mitochondria: a role in neurodegeneration |
| Q34286028 | Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis |
Search more.